On the other hand, some CDK9 agents, such as dinaciclib, failed in phase III trials in chronic lymphocytic leukemia due to its toxicity profile, suggesting that the therapeutic index of these agents could be narrow [7]. Here, CDK9 is linked to B-cell chronic lymphocytic leukemia.